Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – What’s Next?

Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped down prior to trading on Friday . The stock had previously closed at $11.78, but opened at $11.38. Telix Pharmaceuticals shares last traded at $11.1750, with a volume of 34,931 shares traded.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Tuesday. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Citigroup reduced their target price on shares of Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Stock Performance

The firm has a 50-day moving average of $10.34 and a 200 day moving average of $8.95. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Insider Activity at Telix Pharmaceuticals

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch purchased 34,500 shares of the stock in a transaction dated Tuesday, April 28th. The shares were bought at an average cost of $14.48 per share, with a total value of $499,560.00. Following the completion of the acquisition, the chief executive officer owned 20,709,500 shares of the company’s stock, valued at approximately $299,873,560. This trade represents a 0.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers increased its stake in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares during the period. Bank of America Corp DE lifted its stake in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the period. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals in the fourth quarter valued at approximately $89,000. XY Capital Ltd bought a new position in shares of Telix Pharmaceuticals in the first quarter valued at approximately $120,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Telix Pharmaceuticals during the second quarter valued at approximately $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.